In contrast, the effectiveness of MTA is not related with mode of CD8 + T cell activation, but rather inhibition of multi-tyrosine kinase activity, thus MTA should be effective irrespective of HCC etiology including in NAFLD/NASH-related HCC cases. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatotic liver disease.